Search results

  1. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  2. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  3. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

  4. Constipation in children and young people: diagnosis and management (CG99)

    This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.

  5. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults

  6. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

  7. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis

  8. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults

  9. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults

  10. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults

  11. Obesity: working with local communities (PH42)

    This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.

  12. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  13. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults

  14. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.

  15. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

    This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.

  16. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary hip fracture programme to help people recover faster and regain their mobility.

  17. Intravenous fluid therapy in adults in hospital (CG174)

    This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.

  18. Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158)

    This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.

  19. Alcohol-use disorders: diagnosis and management of physical complications (CG100)

    This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.

  20. Sexually transmitted infections: condom distribution schemes (NG68)

    This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.

  21. Irritable bowel syndrome in adults: diagnosis and management (CG61)

    This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

  22. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.